While the CLK inhibitor KH-CB19 reduced the pro-angiogenic potential of lung cancer cells under hypoxia by altering the expression pattern of tissue factor splice variants [57], inhibiting CLKs in podocytes seems to favor the splicing of VEGF toward pro-angiogenic isoforms [58], which appears to contrast the results from the previous study. The gene discussed is CLK1; the disease is lung cancer.